Car-T细胞疗法-话题@MedSci

#Car-T细胞疗法#

56篇内容 | 3003人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1291586, encodeId=2f4a129158643, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤, objectType=article, longId=723516, objectId=7576e23516c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7576e23516c3, replyNumber=0, likeNumber=91, createdTime=2022-04-06, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7576e23516c3, moduleTitle=CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7576e23516c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291585, encodeId=3eec12915855b, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=FDA公布基因编辑与CAR-T细胞疗法两份指南草案，提出这些建议, objectType=article, longId=301462, objectId=79c4301462ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79c4301462ab, replyNumber=0, likeNumber=79, createdTime=2022-03-24, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79c4301462ab, moduleTitle=FDA公布基因编辑与CAR-T细胞疗法两份指南草案，提出这些建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79c4301462ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291584, encodeId=d99c12915848f, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=由于患者死亡，CAR-T细胞疗法ATA2271的临床试验被暂停, objectType=article, longId=299319, objectId=aae0299319f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aae0299319f3, replyNumber=0, likeNumber=79, createdTime=2022-02-23, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aae0299319f3, moduleTitle=由于患者死亡，CAR-T细胞疗法ATA2271的临床试验被暂停, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aae0299319f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291583, encodeId=de7912915838c, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=NEJM：CAR-T细胞疗法首次成功治疗红斑狼疮, objectType=article, longId=215829, objectId=75e621582978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75e621582978, replyNumber=0, likeNumber=78, createdTime=2021-08-18, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75e621582978, moduleTitle=NEJM：CAR-T细胞疗法首次成功治疗红斑狼疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75e621582978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291582, encodeId=a390129158230, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, objectType=article, longId=212729, objectId=d16b212e29ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16b212e29ab, replyNumber=0, likeNumber=85, createdTime=2021-06-16, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16b212e29ab, moduleTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16b212e29ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291581, encodeId=986e1291581ca, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果, objectType=article, longId=211106, objectId=51f721110637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51f721110637, replyNumber=0, likeNumber=99, createdTime=2021-05-12, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51f721110637, moduleTitle=NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51f721110637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291580, encodeId=94c7129158044, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL, objectType=article, longId=210740, objectId=e5eb210e403b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5eb210e403b, replyNumber=0, likeNumber=60, createdTime=2021-05-03, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5eb210e403b, moduleTitle=Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5eb210e403b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291579, encodeId=472812915e9be, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, objectType=article, longId=209158, objectId=40ec209158b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ec209158b9, replyNumber=0, likeNumber=83, createdTime=2021-03-31, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ec209158b9, moduleTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ec209158b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291578, encodeId=f70d12915e860, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准, objectType=article, longId=209107, objectId=d5a420910e55, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5a420910e55, replyNumber=0, likeNumber=67, createdTime=2021-03-29, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5a420910e55, moduleTitle=BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5a420910e55)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291577, encodeId=49e412915e7be, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Nat Commun：CD318、TSPAN8和CD66c为胰腺癌CAR-T细胞疗法的候选靶标, objectType=article, longId=208290, objectId=058f2082904e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=058f2082904e, replyNumber=0, likeNumber=76, createdTime=2021-03-13, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=058f2082904e, moduleTitle=Nat Commun：CD318、TSPAN8和CD66c为胰腺癌CAR-T细胞疗法的候选靶标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=058f2082904e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291576, encodeId=cc5612915e617, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=NICE：欧洲套细胞淋巴瘤患者将从CAR-T细胞疗法中全面受益！, objectType=article, longId=207682, objectId=34c920e68265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34c920e68265, replyNumber=0, likeNumber=95, createdTime=2021-02-28, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34c920e68265, moduleTitle=NICE：欧洲套细胞淋巴瘤患者将从CAR-T细胞疗法中全面受益！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34c920e68265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291575, encodeId=125d12915e523, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=NEJM：BCMA靶向CAR-T细胞疗法Idecabtagene Vicleucel（Ide-cel）取得积极结果, objectType=article, longId=207624, objectId=eba320e6248f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba320e6248f, replyNumber=0, likeNumber=66, createdTime=2021-02-27, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba320e6248f, moduleTitle=NEJM：BCMA靶向CAR-T细胞疗法Idecabtagene Vicleucel（Ide-cel）取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba320e6248f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291574, encodeId=6d9012915e4ec, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, objectType=article, longId=206908, objectId=2d6520690891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6520690891, replyNumber=0, likeNumber=67, createdTime=2021-02-09, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6520690891, moduleTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6520690891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291573, encodeId=ec6112915e300, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Lenzilumab预防或治疗与CAR-T细胞疗法相关细胞因子风暴和神经毒性, objectType=article, longId=204991, objectId=a8c8204991ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8c8204991ff, replyNumber=0, likeNumber=83, createdTime=2020-12-31, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8c8204991ff, moduleTitle=Lenzilumab预防或治疗与CAR-T细胞疗法相关细胞因子风暴和神经毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8c8204991ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291572, encodeId=04b112915e298, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=CRISPR编辑的CAR-T细胞疗法增强了对抗血癌的能力, objectType=article, longId=204328, objectId=6b2e20432812, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b2e20432812, replyNumber=0, likeNumber=74, createdTime=2020-12-10, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b2e20432812, moduleTitle=CRISPR编辑的CAR-T细胞疗法增强了对抗血癌的能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b2e20432812)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291571, encodeId=793112915e11e, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, objectType=article, longId=201543, objectId=a72820154315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a72820154315, replyNumber=0, likeNumber=82, createdTime=2020-10-04, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a72820154315, moduleTitle=CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a72820154315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291570, encodeId=731a12915e065, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=Nat Med ：新型双CAR-T细胞疗法，快速清除体内HIV病毒，持久保护, objectType=article, longId=200191, objectId=d92e20019135, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d92e20019135, replyNumber=0, likeNumber=105, createdTime=2020-09-05, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d92e20019135, moduleTitle=Nat Med ：新型双CAR-T细胞疗法，快速清除体内HIV病毒，持久保护, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d92e20019135)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291569, encodeId=b8c1129156965, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=同种异体CAR-T细胞疗法治疗白血病，获得FDA的快速通道指定, objectType=article, longId=199754, objectId=3106199e5420, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3106199e5420, replyNumber=0, likeNumber=64, createdTime=2020-08-22, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3106199e5420, moduleTitle=同种异体CAR-T细胞疗法治疗白血病，获得FDA的快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3106199e5420)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291568, encodeId=c4dd129156899, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, objectType=article, longId=198425, objectId=61571984251d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61571984251d, replyNumber=0, likeNumber=86, createdTime=2020-08-01, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61571984251d, moduleTitle=CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61571984251d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1291567, encodeId=1aae129156ebe, content=<a href='/topic/show?id=2acd40e7ba' target=_blank style='color:#2F92EE;'>#Car-T细胞疗法#</a>, objectTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, objectType=article, longId=198053, objectId=701319805312, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=701319805312, replyNumber=0, likeNumber=80, createdTime=2020-07-27, rootId=0, userName=changjitao2009, userId=db7c233, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=701319805312, moduleTitle=FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=701319805312)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Car-T细胞疗法

2020-05-29

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

CAR-T细胞疗法Yescarta获得FDA批准用于早期治疗淋巴瘤

2022-04-06

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

FDA公布基因编辑与CAR-T细胞疗法两份指南草案，提出这些建议

2022-03-24

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

由于患者死亡，CAR-T细胞疗法ATA2271的临床试验被暂停

2022-02-23

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

NEJM：CAR-T细胞疗法首次成功治疗红斑狼疮

2021-08-18

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响

2021-06-16

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果

2021-05-12

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL

2021-05-03

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤

2021-03-31

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准

2021-03-29

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Nat Commun：CD318、TSPAN8和CD66c为胰腺癌CAR-T细胞疗法的候选靶标

2021-03-13

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

NICE：欧洲套细胞淋巴瘤患者将从CAR-T细胞疗法中全面受益！

2021-02-28

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

NEJM：BCMA靶向CAR-T细胞疗法Idecabtagene Vicleucel（Ide-cel）取得积极结果

2021-02-27

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！

2021-02-09

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Lenzilumab预防或治疗与CAR-T细胞疗法相关细胞因子风暴和神经毒性

2020-12-31

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

CRISPR编辑的CAR-T细胞疗法增强了对抗血癌的能力

2020-12-10

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

CAR-T细胞疗法MB-102治疗BPDCN、AML、hrMDS：即将开展多中心I/II期临床试验

2020-10-04

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

Nat Med ：新型双CAR-T细胞疗法，快速清除体内HIV病毒，持久保护

2020-09-05

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

同种异体CAR-T细胞疗法治疗白血病，获得FDA的快速通道指定

2020-08-22

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

CAR-T细胞疗法Idecabtagene Vicleucel治疗复发难治多发性骨髓瘤：已提交BLA

2020-08-01

changjitao2009 (审核中...)

前往app查看评论内容

#Car-T细胞疗法#

FDA批准CAR-T细胞疗法Tecartus治疗复发难治套细胞淋巴瘤

2020-07-27

科室
- - 订阅+
  - 更多科室
工具
服务